CGA-IGC Partnership Announcement

CGA-IGC Partnership Announcement

LS CancerDiag entered a new partnership with The Collaborative Group of the Americas on Inherited Gastrointestinal Cancer

As we honored the #HereditaryCancerWeek last week, we took the occasion to announce our partnership with CGA-IGC.

The Collaborative Group of the Americas on Inherited Gastrointestinal Cancer, CGA-IGC, is an organization established in 1995 that brings together colorectal surgeons, medical oncologists, gastroenterologists, researchers, geneticists, nurses, colorectal cancer registry coordinators, genetic counselors, psychologists, and all other health care professionals involved in the care of individuals with hereditary gastrointestinal cancer to improve understanding of the basic science and the clinical management of inherited gastrointestinal cancers.

The vision of the CGA-IGC is to eliminate morbidity and early mortality of hereditary gastrointestinal cancers.

The CGA-IGC vision is very aligned with LS CancerDiag’s mission of empowering families and healthcare professionals to make better informed decisions for cancer prevention. And in terms of our values the company could hardly wish for a better suited partnership. Both organization share the deep wish to create and share knowledge in service of advancing this important field of research and to improve our understanding of the complexity related to  hereditary cancer predispositions.

CGA-IGC Annual Meeting 2022

The mission of the CGA-IGC is to advance science and clinical care of inherited gastrointestinal cancers through research and education as the leading authority in the Americas.

The highlight for the 2023 partnership will be to support the CGA-IGC Annual Meeting, taking place in Las Vegas from the 26th to the 28th of October, an event showcasing cutting-edge developments in the field, including groundbreaking research and clinical paradigm shifts. LS CancerDiag will also join this collaborative event that aims to share knowledge and up-to-date information on new developments in hereditary gastrointestinal cancer research, including implications in the prevention, diagnosis, and treatment of patients with hereditary cancer syndromes.

“We are pleased to partner with the LS CancerDiag and extremely grateful for their support. This allows us to continue being a key resource for individuals and institutions working in the field of inherited gastrointestinal cancer syndromes, including Lynch Syndrome, by supporting professional growth and improving patient outcomes by expanding access to up-to-date information of interest to the multidisciplinary healthcare team and researchers”, says 2023 CGA-IGC president & gastroenterologist, Dr. Peter Stanich.

“LS CancerDiag is privileged to support the significant efforts CGA-IGC is taking within the expert community around hereditary gastrointestinal cancer. We share the common purpose of improving cancer management through advanced science and clinical care; thus, we are pleased to contribute to their valuable efforts in providing a high-quality and accessible platform for educating, sharing knowledge, and finding resources”, says LS CancerDiag Head of Culture and Communication Philippe Arnez.

Through the alliance with CGA-IGC, LS CancerDiag wants to support the organization’s high-yield activities to its engaged, multidisciplinary members. Those activities encompass much more than the annual meeting, and include resources such as journal scans, webinars, and an own podcast.

The aim of CGA-IGC is to help its members, the hereditary cancer care professionals, in their daily practice, and LS CancerDiag is proud to be part of those efforts. After an initial engagement last year, we are looking forward to deepening our relationship with the CGA-IGC society and nurture this fruitful collaboration over the coming years.

LS CancerDiag CEO Niklas Lahti, and Head of Culture and Communication Philippe Arnez at the 2022 CGA Meeting

To learn more about CGA-IGC, please visit their website at

Invest today!

LS CancerDiag has launched a funding round in collaboration with Springvest

The company aims to raise €5.4M in capital to support the expansion into the United States and introduce DiagMMR® to the largest health care market in the world.